top of page

Lab testing for doxy-PEP programs: what sexual health programs need

2 days ago
5 min read
Illustration of a doxy-PEP testing program: a rack of swab and blood specimen tubes, a calendar inside a repeating cycle of arrows for screening every 3 to 6 months, a results checklist, a capsule and a shield, in navy, pink and white

A doxy-PEP program needs the same lab backbone as a strong sexual health program: gonorrhea and chlamydia NAAT at every exposed site, syphilis serology and HIV testing at baseline, then repeat testing every 3–6 months. CDC's 2024 guidelines tie doxy-PEP to ongoing screening, so lab logistics decide whether the program works.


This guide is for telehealth platforms, LGBTQ+ health clinics and sexual health programs adding doxycycline post-exposure prophylaxis (doxy-PEP). It covers what testing the guidelines call for and what to ask a lab partner. It is general information, not medical advice. Ordering clinicians decide which tests each patient needs.



What CDC recommends


CDC published its Clinical Guidelines on the Use of Doxycycline Postexposure Prophylaxis for Bacterial STI Prevention in MMWR Recommendations and Reports in June 2024 (MMWR Recomm Rep 2024;73(No. RR-2)). As of November 2026, CDC's doxy-PEP page for providers still points to these as the current guidelines.


The key points for program planning:


  • Who: CDC recommends counseling gay, bisexual and other men who have sex with men (MSM) and transgender women who had syphilis, chlamydia or gonorrhea in the past 12 months. Clinicians may also discuss it with other MSM and transgender women at increased risk.

  • What: a 200 mg dose of doxycycline taken as soon as possible within 72 hours after oral, vaginal or anal sex, with no more than 200 mg in 24 hours.

  • Evidence: in three large randomized trials, doxy-PEP reduced syphilis and chlamydia by more than 70% and gonorrhea by about 50%.

  • Limits: CDC makes no recommendation yet for cisgender women, cisgender heterosexual men, transgender men, or other queer and nonbinary people. The one trial in cisgender women found no significant reduction in bacterial STIs.


Most importantly for lab planning, CDC says doxy-PEP should sit inside a comprehensive sexual health approach that includes STI screening and treatment and linkage to HIV PrEP or HIV care.



The testing schedule doxy-PEP programs need


The guidelines call for bacterial STI testing at the anatomic sites of exposure at baseline and every 3–6 months after that. Box 2 of the guidelines spells out the tests.



At baseline


  • Gonorrhea and chlamydia NAAT at each site of exposure: urine or urethral, rectal and pharyngeal, as the patient's history indicates.

  • Syphilis serology.

  • HIV testing for patients without HIV, following CDC's PrEP guidelines for those on PrEP.

  • Hepatitis B and C screening, which CDC lists as an additional service to consider, along with vaccination where needed.



Every 3–6 months


  • Repeat gonorrhea and chlamydia NAAT at exposed sites and syphilis serology.

  • Repeat HIV testing for patients without HIV.

  • Reassess whether the patient still needs doxy-PEP.


The follow-up interval should match the patient's HIV prevention plan. CDC's clinical guidance for PrEP calls for an HIV antigen/antibody test and an HIV-1 RNA test at least every 3 months for patients on oral PrEP. For people without HIV who are not on PrEP, the doxy-PEP guidelines suggest considering STI and HIV screening every 3–6 months.



Why the screening schedule matters more with doxy-PEP


Doxy-PEP reduces infections. It does not eliminate them. CDC's patient guidance notes that the doxy-PEP dose is not strong enough to treat an STI, and that doxy-PEP does not prevent HIV, herpes or other viral STIs.


That puts routine screening at the center of the program for three reasons:


  • Breakthrough infections still need diagnosis and treatment. Gonorrhea is the infection doxy-PEP prevents least well.

  • Resistance is an open question. CDC says studies aren't yet enough to judge the long-term effect on antimicrobial resistance in STIs and in other bacteria, such as Staphylococcus aureus, or on the microbiome. CDC is monitoring resistance trends as use grows.

  • The visit is the checkpoint. Each follow-up is when clinicians reassess the need for doxy-PEP and give enough doses to last until the next visit. A missed lab visit can stall the whole cycle.



Why extragenital testing is not optional


Doxy-PEP is meant for patients with exposure at several anatomic sites, and urine-only testing misses rectal and throat infections. CDC's STI screening recommendations call for gonorrhea screening in sexually active MSM at sites of contact (urethra, rectum and pharynx). They recommend screening every 3–6 months for those at increased risk.


In 2019, FDA cleared the first NAAT assays for throat and rectal specimens. Before that, no chlamydia or gonorrhea test was cleared for throat or rectal samples. When you evaluate a lab, ask which assay and specimen types it uses for each site and whether self-collected swabs are validated.


For a site-by-site look at kit design, see our guide to white-label 3-site STI test kits.



Questions to ask a lab partner


Use these questions to compare labs for a doxy-PEP or combined PrEP and doxy-PEP program:


  • Panel flexibility: Can your clinicians build one order that covers 3-site NAAT, syphilis serology, HIV testing and hepatitis screening, with the sites chosen per patient?

  • Specimen validation: Which specimens are validated for each test? Swab-based NAAT can work with self-collection. Syphilis serology and HIV testing need blood, so confirm how the blood specimen is collected for each test.

  • Collection options: Can patients use at-home kits, a draw site or both? Plan for patients who need an in-person draw.

  • Schedule support: Can recurring orders follow a 3-month cadence that matches PrEP monitoring, so patients aren't sent through two separate testing cycles?

  • Results routing: Do results flow to your platform or EHR by API or portal before the follow-up visit, with clear flags for positives?

  • Positive-result workflow: How does the lab handle reportable results under state law, and how quickly are positives communicated to your ordering clinician?

  • Licensure and coverage: Is the lab CLIA-certified and licensed in the states where your patients live?



Fitting doxy-PEP into an existing PrEP program


Most programs that offer doxy-PEP already run PrEP, and the testing overlaps heavily. CDC's PrEP guidance already includes STI screening at least every 3 months for gay and bisexual men with risk factors for recurrent bacterial STIs. A combined program can usually use one quarterly panel and one collection event rather than two.


Our PrEP lab-monitoring checklist covers the HIV, kidney function and STI elements for oral and injectable PrEP. Add the doxy-PEP-specific steps, such as reassessing need and checking side effects, to the clinician's visit template rather than the lab order.



Planning notes


  • Build around the current guideline. Track CDC updates, since CDC says it will revise the guidelines as data on other populations and resistance come in.

  • Keep eligibility logic with clinicians. The lab runs what is ordered. Eligibility, prescribing and counseling belong to your clinical team.

  • Measure completion, not just orders. Track how many patients complete each 3–6 month panel, including all exposed sites.


IHDLab is a CLIA-certified, over 51% LGBTQ+-owned lab licensed in California, New York and Maryland that works with sexual health programs on PrEP and STI lab testing. If you're mapping a doxy-PEP testing workflow, our team is happy to talk through panel options.

bottom of page